New Drug Developed by Dr. Cushman Enters Phase 1 Clinical Trials
March 28, 2017 - The National Cancer Institute (NCI) has begun a Phase I study titled "Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas". LMP744 is a new drug developed by Dr. Mark Cushman, Distinguished Professor of Medicinal Chemistry. This is the third drug from the Cushman laboratory to enter Phase 1 clinical trials at the NCI. “We are grateful for the support and encouragement that we have received from our collaborators at the National Cancer Institute, and from our colleagues in the Purdue Center for Cancer Research,” says Dr. Cushman. Read more here.